Literature DB >> 9379050

Sensitive responses of leukocytes to lipopolysaccharide require a protein distinct from CD14 at the cell surface.

T Vasselon1, R Pironkova, P A Detmers.   

Abstract

Responses of leukocytes to low concentrations of LPS require the expression of membrane-associated CD14 (mCD14) on the cell surface; mCD14 is, however, a glycosyl-phosphatidylinositol-anchored protein and, therefore, a poor candidate for transducing signals across the plasma membrane. The role of other cell surface proteins in responses of leukocytes to LPS was tested by measuring IL-6 secretion of cultured human monocytes and adhesion of PMN in response to LPS after treatment of the cells with trypsin. Trypsin abolished leukocyte integrin-mediated adhesion of PMN in response to LPS, but the trypsinized cells remained responsive to the alternate agonists TNF, formyl peptide, and PMA. Similarly, trypsin treatment of monocytes inhibited IL-6 production in response to LPS, but not to formyl peptide or PMA. No change in cell surface expression of mCD14 was observed by cytofluorometry, and no proteolysis of mCD14 was detected by immunoblot analysis. These results suggest that digestion of a cell surface protein distinct from mCD14 must account for the loss of responsiveness to LPS. The uptake by monocytes of [3H]LPS presented in LPS-soluble CD14 complexes was also inhibited by trypsin treatment. Monomeric LPS was taken up superstoichiometrically to mCD14 with a ratio of up to 15:1, and trypsin treatment decreased this uptake by more than half. This suggests that a cell surface protein may function in accepting LPS from mCD14. Together the results suggest that one or more trypsin-sensitive cell surface proteins distinct from CD14 participate in both the uptake of LPS by leukocytes and the initiation of the signaling process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379050

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Synthesis and surface expression of CD14 by human endothelial cells.

Authors:  H P Jersmann; C S Hii; G L Hodge; A Ferrante
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages.

Authors:  A Ding; N Thieblemont; J Zhu; F Jin; J Zhang; S Wright
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation.

Authors:  K Le-Barillec; M Si-Tahar; V Balloy; M Chignard
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism.

Authors:  Y C Chen; S Y Wang; C C King
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  CD14 expression and binding of lipopolysaccharide to alveolar macrophages and monocytes.

Authors:  T S Haugen; B Nakstad; O H Skjønsberg; T Lyberg
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

6.  Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.

Authors:  Cheng Cheng; Lingshu Wang; LingShu Wang; Jason G D Gall; Martha Nason; Richard M Schwartz; M Juliana McElrath; Steven C DeRosa; John Hural; Lawrence Corey; Susan P Buchbinder; Gary J Nabel
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

7.  Internalization of monomeric lipopolysaccharide occurs after transfer out of cell surface CD14.

Authors:  T Vasselon; E Hailman; R Thieringer; P A Detmers
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

8.  Transport of bacterial lipopolysaccharide to the golgi apparatus.

Authors:  N Thieblemont; S D Wright
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

9.  Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo, whereas in vivo responses remain intact.

Authors:  M M Wurfel; B G Monks; R R Ingalls; R L Dedrick; R Delude; D Zhou; N Lamping; R R Schumann; R Thieringer; M J Fenton; S D Wright; D Golenbock
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

10.  Toll, a new piece in the puzzle of innate immunity.

Authors:  S D Wright
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.